Multivariate analysis (Cox model) of mPFS and mOS for patients with a response of PR or better after first-line therapy (n = 559)
| Variables . | mPFS . | mOS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| TBR ≤3 vs >3 mo | 1.92 | 1.49-2.47 | <.001 | 2.84 | 1.99-4.05 | <.001 |
| Age ≥65 vs <65 y | 0.97 | 0.72-1.32 | .853 | 2.66 | 2.24-2.42 | .008 |
| Response | ||||||
| CR vs VGPR | 0.88 | 0.66-1.16 | .365 | 1.24 | 0.86-1.79 | .251 |
| CR vs PR | 0.43 | 0.31-0.59 | <.001 | 0.75 | 0.49-1.15 | .181 |
| ISS clinical stage | ||||||
| I vs II | 0.81 | 0.63-1.05 | .108 | 0.75 | 0.55-1.03 | .074 |
| I vs III | 0.71 | 0.52-0.98 | .036 | 0.37 | 0.23-0.59 | <.001 |
| High-risk vs standard-risk cytogenetics | 1.28 | 1.00-1.62 | .048 | 1.57 | 1.15-2.14 | .005 |
| Treatment regimens | ||||||
| IMiD containing, yes vs no | 1.27 | 0.88-1.84 | .207 | 1.27 | 0.84-1.92 | .257 |
| PI containing, yes vs no | 1.34 | 0.96-1.88 | .087 | 0.92 | 0.58-1.45 | .708 |
| Transplantation, yes vs no | 0.81 | 0.60-1.08 | .154 | 1.04 | 0.70-1.55 | .843 |
| Variables . | mPFS . | mOS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| TBR ≤3 vs >3 mo | 1.92 | 1.49-2.47 | <.001 | 2.84 | 1.99-4.05 | <.001 |
| Age ≥65 vs <65 y | 0.97 | 0.72-1.32 | .853 | 2.66 | 2.24-2.42 | .008 |
| Response | ||||||
| CR vs VGPR | 0.88 | 0.66-1.16 | .365 | 1.24 | 0.86-1.79 | .251 |
| CR vs PR | 0.43 | 0.31-0.59 | <.001 | 0.75 | 0.49-1.15 | .181 |
| ISS clinical stage | ||||||
| I vs II | 0.81 | 0.63-1.05 | .108 | 0.75 | 0.55-1.03 | .074 |
| I vs III | 0.71 | 0.52-0.98 | .036 | 0.37 | 0.23-0.59 | <.001 |
| High-risk vs standard-risk cytogenetics | 1.28 | 1.00-1.62 | .048 | 1.57 | 1.15-2.14 | .005 |
| Treatment regimens | ||||||
| IMiD containing, yes vs no | 1.27 | 0.88-1.84 | .207 | 1.27 | 0.84-1.92 | .257 |
| PI containing, yes vs no | 1.34 | 0.96-1.88 | .087 | 0.92 | 0.58-1.45 | .708 |
| Transplantation, yes vs no | 0.81 | 0.60-1.08 | .154 | 1.04 | 0.70-1.55 | .843 |